Decreased Hsp90 expression in infiltrative lobular carcinoma: An immunohistochemical study

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Zagouri, Flora ^a   Sergentanis, Theodoros ^a   Nonni, Afrodite ^a   Papadimitriou, Christos ^a   Pazaiti, Anastasia ^a   Michalopoulos, Nikolaos V ^a   Safioleas, Panagiotis ^a   Lazaris, Andreas ^a   Theodoropoulos, George ^a   Patsouris, Effstratios ^a   Zografos, George ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

HEAT SHOCK PROTEIN 90;

ADULT; AGED; ARTICLE; BREAST DUCT; CANCER INFILTRATION; CANCER INVASION; CARCINOMA CELL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; DISEASE ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTRADUCTAL CARCINOMA; PROTEIN EXPRESSION; BREAST; BREAST TUMOR; ENZYME IMMUNOASSAY; LUNG CARCINOMA; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS;

ADULT; AGED; BREAST; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; PROGNOSIS;

EID: 77955211364     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-409     Document Type: Article

References (25)

1. Lai BT, Chin NW, Stanek AE, Keh W, Lanks KW. Quantitation and intracellular localization of the 85 K heat shock protein by using monoclonal and polyclonal antibodies. Mol Cell Biol 1984, 4:2802-2810. 369291, 6396506.
2. Whitley D, Goldberg SP, Jordan WD. Heat shock proteins: a review of the molecular chaperones. J Vasc Surg 1999, 29:748-751. 10.1016/S0741-5214(99)70329-0, 10194511.
3. Beliakoff J, Whitesell L. Hsp90: an emerging target for breast cancer therapy. Anticancer Drugs 2004, 15:651-662. 10.1097/01.cad.0000136876.11928.be, 15269596.
4. Conroy SE, Latchman DS. Do heat shock proteins have a role in breast cancer?. Br J Cancer 1996, 74:717-721. 2074714, 8795573.
5. Yano M, Naito Z, Tanaka S, Asano G. Expression and roles of heat shock proteins in human breast cancer. Jpn J Cancer Res 1996, 87:908-915.
6. Yano M, Naito Z, Yokoyama M, Shiraki Y, Ishiwata T, Inokuchi M, Asano G. Expression of hsp90 and cyclin D1 in human breast cancer. Cancer Lett 1999, 137:45-51. 10.1016/S0304-3835(98)00338-3, 10376793.
7. Pick E, Kluger Y, Giltnane JM, Moeder C, Camp RL, Rimm DL, Kluger HM. High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res 2007, 67:2932-2937. 10.1158/0008-5472.CAN-06-4511, 17409397.
8. Kim LS, Lee HS, Choi JW, Kang HJ, Price JE. The role of heat shock protein 90/70 as potential molecular therapeutic targets in breast cancer. Proceedings of the 90th annual meeting of the American Association for Cancer Research: 16-20 April 2005, Anaheim, CA 2005, 2346. Philadelphia, PA; AACR.
9. Miyata Y. Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents. Curr Pharm Des 2005, 11:1131-1138. 10.2174/1381612053507585, 15853661.
10. Bagatell R, Whitesell L. Altered Hsp90 function in cancer: a unique therapeutic opportunity. Mol Cancer Ther 2004, 3:1021-1030. 10.4161/cbt.3.10.1142, 15299085.
11. Sõti C, Nagy E, Giricz Z, Vígh L, Csermely P, Ferdinandy P. Heat shock proteins as emerging therapeutic targets. Br J Pharmacol 2005, 146:769-780. 10.1038/sj.bjp.0706396, 1751210, 16170327.
12. Workman P, Burrows F, Neckers L, Rosen N. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann N Y Acad Sci 2007, 1113:202-216. 10.1196/annals.1391.012, 17513464.
13. Holmes JL, Sharp SY, Hobbs S, Workman P. Silencing of HSP90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer Res 2008, 68:1188-1197. 10.1158/0008-5472.CAN-07-3268, 18281495.
14. Zagouri F, Nonni A, Sergentanis TN, Papadimitriou CA, Michalopoulos NV, Lazaris AC, Patsouris E, Zografos GC. Heat shock protein90 in lobular neoplasia of the breast. BMC Cancer 2008, 8:312. 10.1186/1471-2407-8-312, 2588461, 18957107.
15. Schreer I, Luttges J. Precursor lesions of invasive breast cancer. Eur J Radiol 2005, 54:62-71. 10.1016/j.ejrad.2004.11.014, 15797294.
16. Sastre-Garau X, Jouve M, Asselain B, Vincent-Salomon A, Beuzeboc P, Dorval T, Durand JC, Fourquet A, Pouillart P. Infiltrating lobular carcinoma of the breast. Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer 1996, 77:113-120. 10.1002/(SICI)1097-0142(19960101)77:1<113::AID-CNCR19>3.0.CO;2-8, 8630916.
17. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999, 17:1474-81.
18. Mann GB, Fahey VD, Feleppa F, Buchanan MR. Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer. J Clin Oncol 2005, 23:5148-5154. 10.1200/JCO.2005.02.076, 16051956.
19. O'Malley FP, Peder SE. Invasive carcinomas: Special types in Breast Pathology 2006, Elsevier.
20. Modi S, Stopeck AT, Gordon MS, Mendelson D, Solit DB, Bagatell R, Ma W, Wheler J, Rosen N, Norton L, Cropp GF, Johnson RG, Hannah AL, Hudis CA. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol 2007, 25:5410-7. 10.1200/JCO.2007.11.7960, 18048823.
21. Powers MV, Workman P. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer 2006, 13:S125-35. 10.1677/erc.1.01324, 17259553.
22. Solit DB, Rosen N. Hsp90: a novel target for cancer therapy. Curr Top Med Chem 2006, 6:1205-14. 10.2174/156802606777812068, 16842157.
23. Zhang H, Chung D, Yang YC, Neely L, Tsurumoto S, Fan J, Zhang L, Biamonte M, Brekken J, Lundgren K, Burrows F. Identification of new biomarkers for clinical trials of Hsp90 inhibitors. Mol Cancer Ther 2006, 5:1256-64. 10.1158/1535-7163.MCT-05-0537, 16731758.
24. Diehl MC, Idowu MO, Kimmelshue K, York TP, Elmore LW, Holt SE. Elevated expression of nuclear Hsp90 in invasive breast tumors. Cancer Biol Ther 2009, 8:1952-61. 10.4161/cbt.8.20.9639, 19738418.
25. Gebhard B, Schütz G, Ecker RC, Steiner GE, Rudas M, Gnant M, Oehler R. MHC-class-I expression in human breast cancer correlates with nuclear localization of the 90 kDa heat-shock-protein. Anticancer Res 1999, 19:5293-5297.